202 related articles for article (PubMed ID: 18723490)
1. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2.
Kitagaki J; Agama KK; Pommier Y; Yang Y; Weissman AM
Mol Cancer Ther; 2008 Aug; 7(8):2445-54. PubMed ID: 18723490
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53.
Clement JA; Kitagaki J; Yang Y; Saucedo CJ; O'Keefe BR; Weissman AM; McKee TC; McMahon JB
Bioorg Med Chem; 2008 Dec; 16(23):10022-8. PubMed ID: 18977148
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer.
Weissman AM; Yang Y; Kitagaki J; Sasiela CA; Beutler JA; O'Keefe BR
Ernst Schering Found Symp Proc; 2008; (1):171-90. PubMed ID: 19202599
[TBL] [Abstract][Full Text] [Related]
4. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.
Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V
Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds.
Liu LJ; He B; Miles JA; Wang W; Mao Z; Che WI; Lu JJ; Chen XP; Wilson AJ; Ma DL; Leung CH
Oncotarget; 2016 Mar; 7(12):13965-75. PubMed ID: 26883110
[TBL] [Abstract][Full Text] [Related]
6. [Abnormal p53-HDM2 interaction in hematological malignancy].
Tabe Y; Kojima K
Nihon Rinsho; 2014 Jun; 72(6):1042-6. PubMed ID: 25016801
[TBL] [Abstract][Full Text] [Related]
7. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26.
Zhang Y; Wang J; Yuan Y; Zhang W; Guan W; Wu Z; Jin C; Chen H; Zhang L; Yang X; He F
Nucleic Acids Res; 2010 Oct; 38(19):6544-54. PubMed ID: 20542919
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
[TBL] [Abstract][Full Text] [Related]
9. A regulatory loop composed of RAP80-HDM2-p53 provides RAP80-enhanced p53 degradation by HDM2 in response to DNA damage.
Yan J; Menendez D; Yang XP; Resnick MA; Jetten AM
J Biol Chem; 2009 Jul; 284(29):19280-9. PubMed ID: 19433585
[TBL] [Abstract][Full Text] [Related]
10. Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions.
Medina-Medina I; García-Beltrán P; de la Mora-de la Mora I; Oria-Hernández J; Millot G; Fahraeus R; Reyes-Vivas H; Sampedro JG; Olivares-Illana V
Mol Cell Biol; 2016 Aug; 36(16):2195-205. PubMed ID: 27215386
[TBL] [Abstract][Full Text] [Related]
11. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
[TBL] [Abstract][Full Text] [Related]
12. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.
Sosin AM; Burger AM; Siddiqi A; Abrams J; Mohammad RM; Al-Katib AM
J Hematol Oncol; 2012 Sep; 5():57. PubMed ID: 22989009
[TBL] [Abstract][Full Text] [Related]
13. A small HDM2 antagonist peptide and a USP7 inhibitor synergistically inhibit the p53-HDM2-USP7 circuit.
Mukherjee S; Saha G; Roy NS; Naiya G; Ghosh MK; Roy S
Chem Biol Drug Des; 2023 Jul; 102(1):126-136. PubMed ID: 37105726
[TBL] [Abstract][Full Text] [Related]
14. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors suppress the protein expression of mutant p53.
Halasi M; Pandit B; Gartel AL
Cell Cycle; 2014; 13(20):3202-6. PubMed ID: 25485499
[TBL] [Abstract][Full Text] [Related]
16. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
Koblish HK; Zhao S; Franks CF; Donatelli RR; Tominovich RM; LaFrance LV; Leonard KA; Gushue JM; Parks DJ; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Cummings MD; Grasberger BL; Johnson DL; Lu T; Molloy CJ; Maroney AC
Mol Cancer Ther; 2006 Jan; 5(1):160-9. PubMed ID: 16432175
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
Yang Y; Ludwig RL; Jensen JP; Pierre SA; Medaglia MV; Davydov IV; Safiran YJ; Oberoi P; Kenten JH; Phillips AC; Weissman AM; Vousden KH
Cancer Cell; 2005 Jun; 7(6):547-59. PubMed ID: 15950904
[TBL] [Abstract][Full Text] [Related]
19. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
20. A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene.
Bartl S; Ban J; Weninger H; Jug G; Kovar H
Nucleic Acids Res; 2003 Feb; 31(4):1136-47. PubMed ID: 12582232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
